Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218380 · ClinicalTrials.gov registry record · Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT07218380: Recruiting Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms, sponsored by Eli Lilly and Company.
NCT07218380 is a Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants, above the 405-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218380, a Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- OTHER Placebo
- DRUG EV
- DRUG Vepugratinib
Study Locations (20)
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine - Irvine
- TRIO-US (Translational Research in Oncology-US) - Los Angeles
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- UCSF Medical Center at Mission Bay - San Francisco
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN) - Torrance
Indiana
- Parkview Research Center at Parkview Regional Medical Center - Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
- Franciscan Health - Indianapolis
Colorado
- AdventHealth Medical Group - Porter - Denver
- Colorado West Healthcare System - Grand Valley Oncology - Grand Junction
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago Medical Center - Chicago
Alabama
- Clearview Cancer Institute - Huntsville
Arizona
- The University of Arizona Cancer Center - North Campus - Tucson
Florida
- AdventHealth Orlando - Orlando
Idaho
- St. Luke's Cancer Institute: Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2033-05 |
| Phase | Phase 3 |
What NCT07218380 shows while recruiting
NCT07218380 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 405-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (11% higher).
The record links to 3 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT07218380 names 20 study sites across 10 states, led by California, Indiana, Colorado.
Frequently Asked Questions
What is clinical trial NCT07218380 about?
NCT07218380 is a clinical study titled "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract". The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study...
What is the current status of trial NCT07218380?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-12-12. Estimated completion is 2033-05.
What conditions does trial NCT07218380 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell.
What interventions are being tested in trial NCT07218380?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (OTHER), EV (DRUG), Vepugratinib (DRUG).
Who is sponsoring clinical trial NCT07218380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218380 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218380's enrollment target sits among peer trials
450 12th of 41 higher than 30 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI